Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Generation of Yeast Produced Multifunctional Antibody-Based Therapeutics Against Salmonella Gastroenteritis

EF 2017-18

Résumé
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies (NBXs) have been generated andtested for their efficacy using in vitro and in vivo methods. This proposal relies on the expertise of Dr. ChrisLoewen and his laboratory in the fields of yeast genetics, protein production and biochemistry. This work willgenerate yeast strains that can produce and hopefully improve NBXs efficacy in blocking Salmonella infectionin chickens. Additionally, we will develop stable pro-biotic yeast strains expressing NBXs for direct inclusionin chicken feed. Our approach will combine promoters of chicken gastrointestinal health with pathogen specificNBXs that inhibit key virulence pathways. The following steps will be taken to determine the synergisticefficacy of our conjugate approach: (1) NBXs will be engineered to contain sites for glycosylation in yeast. (2)NBXs will be expressed as soluble and membrane bound variants, or both, in Sacchyomyces cerevisiae andPichia pastoris. (3) Soluble NBXs and NBX-producing yeast will be tested in vitro for improved activityagainst Salmonella. (4) The efficacy of NBXs against Salmonella infection will be tested in vivo in chickens.The development of a Salmonella-selective and highly effective antibody would benefit Canadian and worldpopulations by reducing human infection and illness, loss of life, and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
514779-2017
Name nom
Loewen, Christopher
Department département
Cellular and Physiological Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5302
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Gene expression
Research subject fr
Expression génétique
Partie
1
Nb partie
1
Application title
Generation of Yeast Produced Multifunctional Antibody-Based Therapeutics Against Salmonella Gastroenteritis
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies (NBXs) have been generated andtested for their efficacy using in vitro and in vivo methods. This proposal relies on the expertise of Dr. ChrisLoewen and his laboratory in the fields of yeast genetics, protein production and biochemistry. This work willgenerate yeast strains that can produce and hopefully improve NBXs efficacy in blocking Salmonella infectionin chickens. Additionally, we will develop stable pro-biotic yeast strains expressing NBXs for direct inclusionin chicken feed. Our approach will combine promoters of chicken gastrointestinal health with pathogen specificNBXs that inhibit key virulence pathways. The following steps will be taken to determine the synergisticefficacy of our conjugate approach: (1) NBXs will be engineered to contain sites for glycosylation in yeast. (2)NBXs will be expressed as soluble and membrane bound variants, or both, in Sacchyomyces cerevisiae andPichia pastoris. (3) Soluble NBXs and NBX-producing yeast will be tested in vitro for improved activityagainst Salmonella. (4) The efficacy of NBXs against Salmonella infection will be tested in vivo in chickens.The development of a Salmonella-selective and highly effective antibody would benefit Canadian and worldpopulations by reducing human infection and illness, loss of life, and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.